Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.
Hagop M. Kantarjian, MD, professor, and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and the Samsung Distinguished Leukemia Chair in Cancer Medicine, discusses the impact of prominent treatments in acute lymphoblastic leukemia (ALL).
Kantarhijan highlights how the space for treating patients with ALL has moved away from chemotherapy to more targeted therapies, like the Bcr-Abl kinase inhibitor ponatinib (Iclusig), and combination therapies with chemotherapy. He also discusses the potential devoplpment of therapies that are tri-speicfic T-cell engagers allowing for more robust targeting of biomarkers CD19, CD20, and CD22.
0:07 | New generations of Bcr-Abl kinase inhibitors like ponatinib, are showing very promising results in combinations with antibodies like blinatumomab. The antibody cocktails with chemotherapy in pre-BALL are very promising. I'm also interested in the potential development of tri-specific T-cell engagers, instead of bi- specific T cell engagers, meaning that you get the CD3 cells to target CD19 or CD22. So instead of bytes, it will be Trites, where the molecule can target CD19 and CD20 or CD19 and CD22. The same applies for the CAR T-cells, as the CAR T-cells can target more than 1 cluster designation, meaning they could be designed to target both CD19 and CD22, or CD19 and CD20.
1:06 | I think the tri-specific T cell engagers and the CAR T-cells having more than 1 leukemia target are going to be the future "nuclear bombs" against ALL. They will selectively kill the leukemia without the need for maybe intensive chemotherapy, and they should be very effective if they are well designed.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More